Key Takeaways
- Record quarter driven by Switzerland: Revenue grew 34% YoY as Carbogen Amcis commercial revenue jumped from $11.5M to $30.5M, though India API and Quats businesses remained subdued and back-ended.
- Profitability turned positive: EBITDA margin improved to 17.5% from 16.5%, and profit after tax swung to INR 17 crores from INR 4 crores, despite persistent European energy and raw material cost headwinds.
- Regulatory clearance is the unlock: A successful Japanese PMDA inspection at Bavla and an expected EDQM audit in September set the stage for a significant revenue ramp, with management saying post-clearance revenue should exceed pre-COVID levels.
- French facility nearing operational start: First technical batch completed, development work with customers begins in September, and commercial revenue contribution is expected from Q3, though peak revenue of $30–40M remains years away.
- What to watch next quarter: Whether the EDQM audit at Bavla proceeds as planned in September, the pace of India API order conversion in H2, and any early revenue signals from the French facility’s first customer engagements.
Carbogen Amcis Switzerland: The Quarter’s Engine
- Commercial revenue surge: Commercial revenue rose from $11.5M to $30.5M, and Phase 3 revenue also increased significantly, driving the CRAMS segment to 54% revenue growth and an EBITDA margin improvement to 21.7% from 19.4%.
- Pipeline still growing despite biotech headwinds: The pipeline rose 10% QoQ to CHF 12.6 crore even as some market demand eroded from the biotech funding slowdown, with oncology remaining the most dynamic segment.
- I2 suite advantage: Switzerland’s medium-sized capacity and I2 suite expertise allow continued pipeline growth while some larger CMOs struggle to fill their big equipment, because the company competes in a still-active part of the market.
- Clinical trial dependency: Revenue can swing quarter-to-quarter because if a customer’s clinical trial fails, the project is lost, so management is pushing to broaden the customer portfolio to dilute single-project loss risk.
Pascal Villemagne: "We are extremely depending from the success of the clinical trials, from our customer. And yes, from time-to-time, we face some issues, because we have to find a new project to replace the one we just lost. This is a reason why I'm consistent with the sales teams to border the customer portfolio. And the more customer, the more projects we have, the relationship would be to one off a project loss."
Bavla Site: Regulatory Clearance as the Revenue Catalyst
- Japanese PMDA inspection completed successfully: A four-day audit by two PMDA Japan inspectors resulted in a "definitely positive" outcome with very few minor observations; the report is expected in coming weeks and the response is largely prepared.
- EDQM audit is the next gate: The EDQM inspection at Bavla is expected in the second half of September, and clearance would reopen European markets that have been inaccessible since the original observations.
- Post-clearance revenue ramp expected to be significant: Management expects revenue after EDQM clearance to exceed pre-COVID levels, because many existing customers already have purchase orders and selling prices in place, waiting only for clearance to place large orders.
- Bavla revenue recovery trajectory: India standalone revenue dropped from INR 500+ crores to INR 200 crores after the EDQM observations, recovered to INR 300 crores in FY22 and INR 400 crores last year as customers got approvals, but some European geographies still cannot use the APIs without EDQM clearance.
- Margin upside from India ramp: Prior to the EDQM issue, India was doing 40%-plus margins, so the Bavla revenue recovery after clearance should lift operating margin at a faster pace than revenue growth.
Harshil Dalal: "Absolutely. And it should be even higher than that. With the kind of orders that we are expecting from our existing customers, plus, it opens up the door to get more orders from the new customers as well. So, we do expect a significant ramp up in the revenues after the EDQM clearance, in the financial year after EDQM clearance."
French Facility: Investment Phase Nearing Its End
- Operational start imminent: All qualifications are being finalized, the first technical batch has been run, operational work begins by end of August 2023, and first development work with customers starts in September.
- Commercial revenue expected from Q3: The facility is not yet up to commercial production, but revenue contribution should begin in Q3, with peak activities expected in the next 2–3 years depending on sales success for the two filling lines.
- Peak revenue confirmed at $30–40M: Management confirmed the peak revenue number but deflected on the timeline, saying it is "really difficult to say exactly by when" the peak will be reached.
- Cost is already hitting the P&L: €0.27 crore was debited to the P&L for the French facility in Q1 FY24, so the drag is present before the revenue arrives.
Pascal Villemagne: "We are finalizing all the qualifications and we run our first what we so called technical batch, and we should start the operational work by the end of this month. And then starting the first development work with our customers over September, so which is a good news."
India Business: Back-Ended but Promising
- Q1 was the trough: India NCE, APIs and intermediates sales were the lowest in Q1 because most orders are back-ended in Q3 and Q4; margins were subdued due to low revenue but are expected to pick up significantly in the remaining quarters.
- Full-year API target of INR 300+ crores: Management expects to achieve revenue in excess of INR 300 crores for the full FY24 from the India API business, with most orders to be serviced in H2.
- Quats and generics below run-rate: Revenue of INR 30 crores was lower than run-rate expectations, but a pickup is expected in the remaining nine months of FY24.
- Shanghai site transformation paying off: Margins improved to approximately 35% because the site moved from roughly 2 projects 4–5 years ago to 7–8 projects now, acting as an extended branch of the Swiss arm with improvements toward GMP standards.
Phase 3 Pipeline: Commercialisation Is a FY25 Story
- No commercial launches this fiscal year: Of the 15 molecules in Phase 3, two are priced but the customer has no further information from US authorities, so commercialization is most likely next fiscal year; one Japanese customer product is already partially commercial, and another application should enter the commercial stage by 2025.
- ADC linker project tied to 2025: Part of the product is already commercial through the customer, but the facility built for this project will contribute to new ADC applications planned to be marketed by 2025.
- Co-investment agreements provide visibility: The company has co-investment agreements with a Japanese customer for ADC molecule manufacturing and with other US and European biotech customers, with molecules currently manufactured and supplied out of the Swiss entity.
Costs, Debt and the Path to Deleveraging
- Employee costs rose on forex and inflation: Employee expenses increased INR 40 crores, with INR 20 crores from Swiss Franc forex translation and the rest from merit cost increases driven by European inflation.
- Finance costs up on rate hikes: Finance cost rose from INR 19 crores to INR 28 crores due to sustained increases in LIBOR/SOFR rates on foreign-currency-denominated borrowings.
- External headwinds persist: The company is still struggling with energy and raw material costs in Europe, and passing on extra costs to customers is difficult due to contracts or high competition.
- Debt taken for growth, returns expected in 2–3 years: Most debt was raised in the last 2–2.5 years for the French facility, ADC expansion in Switzerland, digital transformation, and India CapEx for regulatory audits; returns from these investments are expected over the next 2–3 years, generating cash flow to reduce net debt.
- CapEx discipline going forward: Run-rate CapEx of CHF 2.5–3 crore per year over the next three years covers maintenance and replacement; any additional CapEx will be backed by a firm contract or purchase order, not done in anticipation of business.
Pascal Villemagne: "Obviously, we are still struggling with a number of external factors depending on the country's especially in Europe, cost of energy and raw materials are still affecting our performance."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue | INR 2,700–2,750 crores | FY24 |
| India API revenue | In excess of INR 300 crores | FY24 |
| French facility operational start | Development work with customers begins | September 2023 |
| French facility commercial revenue | First contribution | Q3 FY24 |
| EDQM audit at Bavla | Inspection to take place | Second half of September 2023 |
| Revenue growth | At least 12–15% per year | Next 3–5 years |
| EBITDA growth | About 15–20% YoY | Ongoing |
| Net debt reduction | Reduce from current levels using free cash flow | Within 3 years |
| Run-rate CapEx | CHF 2.5–3 crore per year | Next 3 years |
| ADC linker commercialisation | New applications marketed | By 2025 |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue | ₹723 cr, +34% YoY from ₹540 cr |
| Full-year revenue guidance | ₹2,700 cr to ₹2,750 cr |
| COGS | ~22% of revenue, vs ~20% annual estimate |
| EBITDA | ~₹127 cr, after excluding SaaS IT cost |
| EBITDA margin | 17.5%, up from 16.5% in Q1 FY23 |
| Finance cost | ₹28 cr, up from ₹19 cr in Q1 FY23 due to higher LIBOR/SOFR rates |
| Profit before tax | ~₹29.5 cr, vs negative ₹3 cr in Q1 FY23 |
| Profit after tax | ₹17 cr, vs ₹4 cr in Q1 FY23 |
| CRAMS segment revenue | ₹561 cr, +54% YoY from ₹363 cr |
| CRAMS segment EBITDA margin | 21.7%, up from 19.4% in Q1 FY23 |
| Cholesterol and Vitamin D analogues revenue | ₹93 cr, +46.7% YoY from ₹63 cr |
| Cholesterol and Vitamin D analogues EBITDA margin | 18.4%, down from 19.3% in Q1 FY23 |
| India quats and generics revenue | ~₹30 cr, lower on run-rate basis; pickup expected in remaining nine months |
| India API full-year revenue target | In excess of ₹300 cr |
| Carbogen Amcis Switzerland commercial revenue | $30.5 mn, up from $11.5 mn in Q1 FY23 |
| Development pipeline value | CHF 12.6 cr, up 10% QoQ |
| French facility P&L cost debited | €0.27 cr in Q1 FY24 |
| French facility purchase orders received | ~$6 mn before commercial start |
| French facility peak revenue target | $30 mn to $40 mn |
| Consolidated FY24 CapEx guidance | $25 mn to $30 mn |
| Run-rate annual CapEx (next 3 years) | CHF 2.5 cr to CHF 3 cr, including maintenance |
| Net debt | CHF 16 cr as of 30 June 2023 |
| Gross debt | CHF 21 cr as of 30 June 2023 |
| Revenue growth guidance (3–5 years) | At least 12% to 15% annually |
| EBITDA growth guidance | 15% to 20% YoY |